跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
BCMA-targeted CAR-T
首页
药物
BCMA-targeted CAR-T
BCMA-targeted CAR-T
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
BCMA-TARGETED CHIMERIC ANTIGEN RECEPTOR AS WELL AS PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
US 2020362048 A1
申请人: CELLULAR BIOMEDICINE GROUP HK LTD
优先权: 2018
CN
EP
US
WO
11 件公开
BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA
EP 4255450 A1
申请人: JANSSEN BIOTECH INC
优先权: 2020
CN
EP
US
WO
7 件公开
EP 4698190 A1
申请人: LEGEND BIOTECH USA INC
优先权: 2023
EP
US
WO
6 件公开
EP 4426737 A1
申请人: JANSSEN BIOTECH INC
优先权: 2021
CN
EP
US
WO
4 件公开
US 20250269024 A1
申请人: LEGEND BIOTECH USA INC
优先权: 2024
US
WO
2 件公开
US 20250339527 A1
申请人: LEGEND BIOTECH USA INC
优先权: 2024
US
WO
2 件公开
CN 118900698 A
申请人: JANSSEN BIOTECH INC
优先权: 2022
CN
BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA
EP 4055049 A1
申请人: JANSSEN BIOTECH INC
优先权: 2019
CN
EP
US
WO
6 件公开
US 2024156962 A1
申请人: LEGEND BIOTECH USA INC
优先权: 2023
US
COMBINATION THERAPY OF ATRA OR OTHER RETINOIDS WITH IMMUNOTHERAPEUTIC AGENTS BINDING TO BCMA
EP 4136111 A1
申请人: UNIV WUERZBURG J MAXIMILIANS
优先权: 2020
CN
EP
US
WO
4 件公开
T cells expressing a chimeric antigen receptor
US 12161668 B2
申请人: MASSACHUSETTS GEN HOSPITAL
优先权: 2017
CN
US
2 件公开
Fusion protein for reversing tumor microenvironment and application thereof
CN 117844761 A
申请人: CHONGQING PREC BIOTECH CO LTD
优先权: 2020
CN
2 件公开
Immune cells expressing chimeric antigen receptor
CN 111819186 A
申请人: MASSACHUSETTS GEN HOSPITAL
优先权: 2018
CN
Construction method and application of chimeric antigen receptor T (CAR-T) cells targeting multiple antigens of multiple myeloma
CN 110577605 A
申请人: ZHEJIANG QIXIN BIOTECHNOLOGY CO LTD
优先权: 2018
CN
Double chimeric antigen receptor gene-modified immune cell based on CD19 and BCMA and application thereof
CN 109468283 A
申请人: BEIJING MEIKANG JIMIAN BIOTECHNOLOGY CO LTD
优先权: 2018
CN
Double chimeric antigen receptor gene-modified immune cell based on CD19 and PSMA and application thereof
CN 109468284 A
申请人: BEIJING MEIKANG JIMIAN BIOTECHNOLOGY CO LTD
优先权: 2018
CN
第 1 / 3 页
上一页
下一页
药物
反馈